本文選題：生長(zhǎng)抑制因子4基因 + 子宮內(nèi)膜癌��； 參考：《鄭州大學(xué)》2015年碩士論文

【摘要】：背景及目的:子宮內(nèi)膜癌是一組由子宮內(nèi)膜惡變形成的惡性腫瘤,是女性生殖系統(tǒng)中的三大惡性腫瘤之一,其組織病理類(lèi)型中以子宮內(nèi)膜樣腺癌最為常見(jiàn),目前,臨床期別較早的子宮內(nèi)膜癌治愈率較高,但是,對(duì)于臨床期別較晚、伴有局部復(fù)發(fā)或遠(yuǎn)處轉(zhuǎn)移的患者,其治愈率仍較低,故早發(fā)現(xiàn)、早治療對(duì)子宮內(nèi)膜癌尤為重要。區(qū)別于宮頸癌,子宮內(nèi)膜癌缺少早期篩查方法,且由于取材局限或誤診為月經(jīng)失調(diào),其早期診斷率較低。因此探索、研究新的檢測(cè)指標(biāo)在子宮內(nèi)膜癌的發(fā)生、發(fā)展、浸潤(rùn)及轉(zhuǎn)移中的作用機(jī)制,將對(duì)子宮內(nèi)膜癌的早期臨床診斷、預(yù)后評(píng)價(jià)產(chǎn)生極大的指導(dǎo)意義。生長(zhǎng)抑制因子家族是近年來(lái)發(fā)現(xiàn)的一組較為重要的腫瘤生長(zhǎng)抑制因子,已有大量研究證明其與體內(nèi)多個(gè)系統(tǒng)腫瘤的發(fā)生有關(guān)。近些年的研究發(fā)現(xiàn),ING4基因在多種腫瘤組織中都有表達(dá)缺失,但是在子宮內(nèi)膜癌中ING4的研究為空白,本研究旨在測(cè)定生長(zhǎng)抑制因子4(ING4)基因在不同病理子宮內(nèi)膜中的表達(dá),并研究其表達(dá)與子宮內(nèi)膜癌發(fā)生、發(fā)展及預(yù)后的關(guān)系。方法:采用免疫熒光PCR方法和免疫組化S-P法檢測(cè)25例正常的增生期子宮內(nèi)膜、15例不典型增生的子宮內(nèi)膜及45例子宮內(nèi)膜樣腺癌組織中ING4的表達(dá)情況,觀(guān)察結(jié)果并進(jìn)行統(tǒng)計(jì)學(xué)處理。結(jié)果:免疫組化S-P法結(jié)果顯示ING4在正常增生期的子宮內(nèi)膜中表達(dá)最多,不典型增生子宮內(nèi)膜組織中的表達(dá)量顯著低于正常增生期子宮內(nèi)膜組織,子宮內(nèi)膜樣腺癌組織中的表達(dá)量最低,3組的比較差異有統(tǒng)計(jì)學(xué)意義(P0.05)。免疫熒光PCR結(jié)果與免疫組化法測(cè)定的結(jié)果相一致,ING4 m RNA的相對(duì)表達(dá)量在正常增生期的子宮內(nèi)膜組織、不典型增生的子宮內(nèi)膜組織、子宮內(nèi)膜樣腺癌的組織中逐漸降低,統(tǒng)計(jì)學(xué)分析顯示,各組間差異有統(tǒng)計(jì)學(xué)意義(P0.05);在子宮內(nèi)膜樣腺癌組織中ING4的表達(dá)與組織學(xué)分級(jí)顯著相關(guān)(P0.05),與肌層浸潤(rùn)深度、淋巴結(jié)轉(zhuǎn)移無(wú)關(guān)(P0.05)。但其表達(dá)與組織-病理學(xué)分期的關(guān)系尚需進(jìn)一步研究。結(jié)論:ING4在子宮內(nèi)膜癌和不典型增生中的表達(dá)有不同程度的丟失,ING4的基因突變或表達(dá)異常甚至缺失可能參與啟動(dòng)了子宮內(nèi)膜癌的惡變過(guò)程。檢測(cè)ING4可能成為子宮內(nèi)膜癌早期診斷及預(yù)測(cè)癌前病變癌變風(fēng)險(xiǎn)重要指標(biāo)之一。
[Abstract]:Background and objective: endometrial carcinoma is a group of malignant neoplasms formed by endometrial malignancy. It is one of the three major malignant tumors in the female reproductive system. Endometrial adenocarcinoma is the most common histopathological type of endometrial carcinoma. The cure rate of early stage endometrial carcinoma is higher, but for the patients with local recurrence or distant metastasis, the cure rate is still low, so early detection, early treatment is particularly important for endometrial carcinoma. Different from cervical cancer, endometrial carcinoma lacks early screening method, and its early diagnosis rate is low because of limited material taken or misdiagnosed as menstrual disorder. Therefore, to explore the role of new detection indicators in the occurrence, development, invasion and metastasis of endometrial carcinoma will be of great significance for the early clinical diagnosis and prognosis evaluation of endometrial carcinoma. The growth inhibitory factor family is a group of important tumor growth suppressor found in recent years, which has been proved to be related to the occurrence of multiple systemic tumors in vivo by a large number of studies. In recent years, it has been found that the expression of ING4 gene is absent in many kinds of tumor tissues, but the study of ING4 in endometrial carcinoma is blank. The purpose of this study is to determine the expression of growth inhibitor 4 (NG4) gene in different pathological endometrium. To study the relationship between its expression and the occurrence, development and prognosis of endometrial carcinoma. Methods: the expression of ING4 in 25 cases of normal proliferative endometrium and 45 cases of endometrioid adenocarcinoma were detected by immunofluorescence PCR method and S-P immunohistochemical method in 15 cases of atypical hyperplasia of endometrium and 45 cases of endometrial adenocarcinoma. The results were observed and statistically analyzed. Results: the results of S-P immunohistochemical staining showed that the expression of ING4 was the most in the endometrium of normal proliferative phase, and the expression of ING4 in atypical hyperplasia endometrium was significantly lower than that in normal proliferative endometrium. There was significant difference among the three groups in the lowest expression of endometrial adenocarcinoma (P 0.05). The relative expression of ING4 m RNA in endometrial tissues of normal proliferative phase, atypical hyperplasia of endometrium and endometrial adenocarcinoma was decreased gradually by immunofluorescence PCR and immunohistochemical method, and the expression of ING4 m RNA in endometrial tissues of normal proliferative phase, atypical hyperplasia of endometrium and endometrial adenocarcinoma was decreased gradually. Statistical analysis showed that there were significant differences among the three groups (P 0.05), and the expression of ING4 in endometrial adenocarcinoma was significantly correlated with histological grade (P 0.05), but not with the depth of myometrial invasion and lymph node metastasis (P 0.05). However, the relationship between its expression and histopathological staging needs further study. Conclusion the gene mutation or abnormal expression of ING4 in endometrial carcinoma and atypical hyperplasia may be involved in the carcinogenesis of endometrial carcinoma. Detection of ING4 may be one of the important markers for early diagnosis of endometrial carcinoma and prediction of the risk of precancerous lesions.
【學(xué)位授予單位】：鄭州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類(lèi)號(hào)】：R737.33

【參考文獻(xiàn)】

相關(guān)碩士學(xué)位論文 前1條

1 王澤民;Survivin、Cox-2、Bcl-2在子宮內(nèi)膜腺癌中的表達(dá)及臨床意義研究[D];蘇州大學(xué);2003年

，

本文編號(hào)：1940034